Mapatumumab

Mapatumumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Mapatumumab is a monoclonal antibody designed for the treatment of cancer. It targets the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor, which plays a role in the process of programmed cell death (apoptosis). By binding to these receptors, mapatumumab can induce apoptosis in tumor cells, potentially leading to a reduction in tumor growth.

Mechanism of Action

Mapatumumab works by specifically binding to the TRAIL receptors, particularly TRAIL-R1, on the surface of tumor cells. This binding activates the receptors and initiates a cascade of events that lead to cell apoptosis. This mechanism is particularly valuable in oncology, as it selectively targets tumor cells while sparing most normal cells.

Clinical Trials

Mapatumumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers, including non-small cell lung cancer, colorectal cancer, and Hodgkin's lymphoma. The outcomes of these trials have provided insights into the potential applications of mapatumumab in cancer therapy, although it has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA).

Development and Research

The development of mapatumumab is part of a broader effort to utilize immune system components to fight cancer. Research continues to focus on improving the efficacy of mapatumumab through combination therapies with other anticancer agents and on identifying the cancer types most likely to respond to this treatment.

See Also

• Monoclonal antibodies
• Apoptosis
• Cancer treatment

   This article is a medical stub. You can help WikiMD by expanding it!